+

WO2000015659A3 - Polypeptide stomacal zsig28 - Google Patents

Polypeptide stomacal zsig28 Download PDF

Info

Publication number
WO2000015659A3
WO2000015659A3 PCT/US1999/021023 US9921023W WO0015659A3 WO 2000015659 A3 WO2000015659 A3 WO 2000015659A3 US 9921023 W US9921023 W US 9921023W WO 0015659 A3 WO0015659 A3 WO 0015659A3
Authority
WO
WIPO (PCT)
Prior art keywords
zsig28
polypeptide
stomach
present
rpv
Prior art date
Application number
PCT/US1999/021023
Other languages
English (en)
Other versions
WO2000015659A2 (fr
Inventor
Paul O Sheppard
Kevin P Foley
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to IL14201299A priority Critical patent/IL142012A0/xx
Priority to CA002343001A priority patent/CA2343001A1/fr
Priority to EP99948205A priority patent/EP1112364A2/fr
Priority to AU61433/99A priority patent/AU6143399A/en
Priority to JP2000570197A priority patent/JP2002524103A/ja
Publication of WO2000015659A2 publication Critical patent/WO2000015659A2/fr
Publication of WO2000015659A3 publication Critical patent/WO2000015659A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des molécules de polynucléotides et de polypeptides de zsig28, nouveau membre de la famille RPV.1 des protéines. Les polynucléotides codant zsig28 peuvent servir à identifier une région du génome liée à des états pathologiques chez l'humain. La présente invention comprend également des procédés pour fabriquer la protéine, leur utilisation et des anticorps de ces molécules.
PCT/US1999/021023 1998-09-16 1999-09-14 Polypeptide stomacal zsig28 WO2000015659A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL14201299A IL142012A0 (en) 1998-09-16 1999-09-14 Stomach polypeptide zsig28
CA002343001A CA2343001A1 (fr) 1998-09-16 1999-09-14 Polypeptide stomacal zsig28
EP99948205A EP1112364A2 (fr) 1998-09-16 1999-09-14 Polypeptide stomacal zsig28
AU61433/99A AU6143399A (en) 1998-09-16 1999-09-14 Stomach polypeptide zsig28
JP2000570197A JP2002524103A (ja) 1998-09-16 1999-09-14 胃ポリペプチドｚｓｉｇ２８

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15444498A 1998-09-16 1998-09-16
US09/154,444 1998-09-16

Publications (2)

Publication Number Publication Date
WO2000015659A2 WO2000015659A2 (fr) 2000-03-23
WO2000015659A3 true WO2000015659A3 (fr) 2000-06-08

Family

ID=22551383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021023 WO2000015659A2 (fr) 1998-09-16 1999-09-14 Polypeptide stomacal zsig28

Country Status (7)

Country Link
EP (1) EP1112364A2 (fr)
JP (1) JP2002524103A (fr)
AU (1) AU6143399A (fr)
CA (1) CA2343001A1 (fr)
IL (1) IL142012A0 (fr)
WO (1) WO2000015659A2 (fr)
ZA (1) ZA200101979B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2396719A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. 22 proteines humaines secretees
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2011256897B2 (en) * 2004-05-18 2013-09-19 Astellas Pharma Inc. Genetic products differentially expressed in tumors and the use thereof
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
MX369276B (es) 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
WO2021111003A1 (fr) 2019-12-06 2021-06-10 SOTIO a.s. Anticorps humanisés anti-cldn18.2
WO2021130291A1 (fr) 2019-12-23 2021-07-01 SOTIO a.s. Anticorps anti-claudin 18.2 spécifiques d'une tumeur
WO2022122709A1 (fr) 2020-12-07 2022-06-16 Sotio Biotech A.S. Conjugués anticorps-médicament à base d'anticorps cldn18.2 humanisés
JP2024500242A (ja) 2020-12-23 2024-01-05 ソティオ バイオテック エイ．エス． 腫瘍特異的クローディン１８．２抗体と薬物との複合体
WO2025078686A1 (fr) 2023-10-12 2025-04-17 Sotio Biotech A.S. Polythérapie impliquant des conjugués anticorps-médicament dirigés contre la claudine 18,2 et des inhibiteurs de l'axe pd1/pd-l pour le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI, Hinxton, UK; 17 August 1996 (1996-08-17), MARRA, M. ET AL: "The WashU-HHMI Mouse EST Project", XP002133447 *
DATABASE EMBL EBI, Hinxton, UK; 30 March 1998 (1998-03-30), MARRA, M. ET AL.: "The WashU Mouse EST Project", XP002133446 *

Also Published As

Publication number Publication date
WO2000015659A2 (fr) 2000-03-23
EP1112364A2 (fr) 2001-07-04
ZA200101979B (en) 2001-10-02
AU6143399A (en) 2000-04-03
JP2002524103A (ja) 2002-08-06
CA2343001A1 (fr) 2000-03-23
IL142012A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
WO2000015659A3 (fr) Polypeptide stomacal zsig28
WO2000058473A3 (fr) Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
EP2189475A3 (fr) Polypeptides de type facteur de croissance des fibroblastes
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
EP1053245A4 (fr) 45 proteines humaines secretees
CA2295999A1 (fr) Proteines nik, acides nucleiques et procedes correspondants
WO1995032221A3 (fr) Autotaxine: proteine stimulant la motilite, utile pour le diagnostic et la therapie du cancer
EP2172478A3 (fr) Facteur III neurotrophe dépendant de l'activité (ADNF III)
WO2000017222A8 (fr) 31 proteines humaines secretees
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
WO2000052136A3 (fr) Enzymes de glycosylation humaines
WO2001042277A3 (fr) Ligands peptidiques complementaires produits a partir du genome humain
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
EP1443055A3 (fr) Interleukines-21 et 22
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
DE69836333D1 (de) Neisseria lactoferrin-bindendes protein
EP0885959A3 (fr) Protéine Wnt-5b humaine
DE69530261D1 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
EP0841399A3 (fr) L'acide nucléotique de fin-1 humaine (une caspase) et séquence de la protéine et ses applications
WO2000000506A3 (fr) Proteines humaines possedant des domaines hydrophobes et adn codant ces proteines
WO2001032878A3 (fr) Phosphatonine: une nouvelle hormone polypeptidique
WO2001012788A3 (fr) Polypeptide ztryp1 de type tryptase
WO2001042292A3 (fr) Nouveau polypeptide secrete zsig87
EP0780472A3 (fr) Protéines de stress

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001/01979

Country of ref document: ZA

Ref document number: 200101979

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 510505

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 142012

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2343001

Country of ref document: CA

Ref country code: CA

Ref document number: 2343001

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 570197

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002823

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999948205

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61433/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999948205

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999948205

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载